Author

Abbas Lugemwa

Observed names: A Lugemwa, Lugemwa, A

Institution: Joint Clinical Research Centre

Observed institutions: University of Padua, Radboud University Nijmegen, University of Zimbabwe, Radboud University Medical Center, Research Institute Hospital 12 de Octubre, MRC Clinical Trials Unit at UCL, Hospital Universitario 12 De Octubre, Baylor College of Medicine Children’s Foundation, Infectious Diseases Institute, Joint Clinical Research Centre, Radboud Institute for Health Sciences, University College London, Makerere University, Medical Research Council

OpenAlex ID: A5088210610

Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa

2014 · Nicholas I. Paton, Cissy Kityo, et al. · New England Journal of Medicine · 213

PDF

Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa

2017 · James Hakim, Victor Musiime, et al. · New England Journal of Medicine · 209

PDF

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial

2022 · Nicholas I Paton, Joseph Musaazi, et al. · The Lancet HIV · 138

PDF

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

2017 · Nicholas I Paton, Cissy Kityo, et al. · The Lancet HIV · 79

PDF

Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial

2020 · Pauline D J Bollen, Cecilia L Moore, et al. · The Lancet HIV · 47

PDF

ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing

2021 · the ODYSSEY Trial Team, Cecilia L. Moore, et al. · BMC Infectious Diseases · 45

PDF

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

2017 · James G Hakim, Jennifer Thompson, et al. · The Lancet Infectious Diseases · 43

PDF

Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

2022 · Hylke Waalewijn, Man K Chan, et al. · The Lancet HIV · 40

Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial

2018 · Cissy Kityo, Alexander J. Szubert, et al. · PLoS Medicine · 38

PDF

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

2022 · Pauline Amuge, Abbas Lugemwa, et al. · The Lancet HIV · 36

PDF

Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial

2018 · Abraham Siika, Leanne McCabe, et al. · Clinical Infectious Diseases · 33

PDF

Peripheral neuropathy in HIV patients in sub-Saharan Africa failing first-line therapy and the response to second-line ART in the EARNEST trial

2015 · For the EARNEST Trial Team, Alejandro Arenas-Pinto, et al. · Journal of NeuroVirology · 32

Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial

2018 · Jane Mallewa, Alexander J Szubert, et al. · The Lancet HIV · 31

PDF

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

2022 · Anna Turkova, Hylke Waalewijn, et al. · The Lancet HIV · 24

PDF

Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial

2023 · Anna Turkova, Ellen White, et al. · The Lancet Child & Adolescent Health · 14

PDF

Twice-Daily Dosing of Dolutegravir in Infants on Rifampicin Treatment: A Pharmacokinetic Substudy of the EMPIRICAL Trial

2023 · Tom G Jacobs, Vivian Mumbiro, et al. · Clinical Infectious Diseases · 12

PDF

Borrowing information across patient subgroups in clinical trials, with application to a paediatric trial

2022 · Rebecca M. Turner, Anna Turkova, et al. · BMC Medical Research Methodology · 11

PDF

Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial

2018 · Jennifer A Thompson, Cissy Kityo, et al. · Clinical Infectious Diseases · 11

PDF

CHAPAS-4 trial: second-line anchor drugs for children with HIV in Africa

2024 · Mutsa Bwakura-Dangarembizi, Alexander J Szubert, et al. · medRxiv · 6

PDF

Population pharmacokinetics of ritonavir as a booster of lopinavir, atazanavir, or darunavir in African children with HIV

2025 · Lufina Tsirizani, Hylke Waalewijn, et al. · Antimicrobial Agents and Chemotherapy · 2

Influence of age and co‐medication on dolutegravir glucuronidation in paediatric patients

2024 · Tom G. Jacobs, Hylke Waalewijn, et al. · British Journal of Clinical Pharmacology · 2

PDF

Population Pharmacokinetics of Dolutegravir in African Children: Results From the CHAPAS-4 Trial

2024 · Hylke Waalewijn, Roeland E Wasmann, et al. · Journal of the Pediatric Infectious Diseases Society · 2

PDF

First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe Pneumonia

2023 · Chishala Chabala, Tom G Jacobs, et al. · Journal of the Pediatric Infectious Diseases Society · 2

PDF

HIV-1 Viral Load and Resistance in Genital Secretions in Patients Taking Protease-Inhibitor-Based Second-Line Therapy in Africa

2017 · Anne Hoppe, Marina Giuliano, et al. · Antiviral Therapy · 2

12-week raltegravir-intensified quadruple therapy versus triple first-line ART reduces viral load more rapidly but does not reduce mortality in severely immunosuppressed African HIV-infected adults and older children: the REALITY trial

2016 · C. Kityo, Abraham Siika, et al. · UCL Discovery (University College London) · 2

Works count: 34

Citation count: 1,259

H-index: 16

I10-index: 21